Doxorubicin-loaded gold nanoparticles for enhanced anticancer efficacy: in vitro, in vivo, and FTIR-based tissue analysis
Amna H. Faid, Ali Abdelaziem, Nehal Ali, Fatma El Zahraa Hussein, Sara Gad, Marwa Sharaky, Heba N. Deif · 2026
Read Doxorubicin-loaded gold nanoparticles for enhanced anticancer efficacy: in vitro, in vivo, and FTIR-based tissue analysis by Amna H. Faid, Ali Abdelaziem, Nehal Ali, Fatma El Zahraa Hussein, Sara Gad, Marwa Sharaky, Heba N. Deif (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13408812.txt.
Description
Amna Faid and co-authors test in 2026 whether loading the chemotherapy drug doxorubicin onto gold nanoparticles can beat drug resistance while sparing healthy tissue. Free doxorubicin damages normal cells and tumours learn to expel it. Their particles were tiny spheres, about thirteen nanometres wide, carrying roughly half their weight potential in drug.
In breast cancer cells the loaded particles halved the dose needed for the same killing effect compared with free drug. In animals, treatment suppressed tumour growth more strongly and stretched median survival by about ten days beyond the free drug. Infrared spectroscopy of tumour tissue added a second readout: the chemical fingerprints of proteins, fats, and nucleic acids shifted partway back toward healthy patterns after treatment. The authors see gold delivery plus spectroscopic monitoring as a promising pairing, pending fuller safety work.
Catalog record
| CREATOR | Amna H. Faid, Ali Abdelaziem, Nehal Ali, Fatma El Zahraa Hussein, Sara Gad, Marwa Sharaky, Heba N. Deif |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25816 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |